MX2023007413A - Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva. - Google Patents
Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva.Info
- Publication number
- MX2023007413A MX2023007413A MX2023007413A MX2023007413A MX2023007413A MX 2023007413 A MX2023007413 A MX 2023007413A MX 2023007413 A MX2023007413 A MX 2023007413A MX 2023007413 A MX2023007413 A MX 2023007413A MX 2023007413 A MX2023007413 A MX 2023007413A
- Authority
- MX
- Mexico
- Prior art keywords
- digoxin
- vibegron
- patient
- monitoring
- overactive bladder
- Prior art date
Links
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 title abstract 6
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 title abstract 6
- 229960005156 digoxin Drugs 0.000 title abstract 6
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 title abstract 6
- DJXRIQMCROIRCZ-XOEOCAAJSA-N vibegron Chemical compound C1([C@H]([C@@H]2N[C@H](CC=3C=CC(NC(=O)[C@H]4N5C(=O)C=CN=C5CC4)=CC=3)CC2)O)=CC=CC=C1 DJXRIQMCROIRCZ-XOEOCAAJSA-N 0.000 title abstract 3
- 229950007643 vibegron Drugs 0.000 title abstract 3
- 206010020853 Hypertonic bladder Diseases 0.000 title abstract 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 208000020629 overactive bladder Diseases 0.000 title abstract 2
- 230000007012 clinical effect Effects 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se refiere a un método para tratar vejiga hiperactiva que comprende administrar por vía oral a un paciente que lo necesita una cantidad terapéuticamente efectiva de vibegron, en donde el paciente está recibiendo digoxina de forma concomitante, en donde el nivel sérico de digoxina del paciente se mantiene en una cantidad que da como resultado un efecto clínico de digoxina deseado. Esto se puede lograr controlando el nivel sérico de digoxina del paciente antes, durante y/o después del tratamiento con Vibegron, y manteniendo o ajustadas la dosis de digoxina con base en ese nivel para lograr el efecto clínico deseado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129474P | 2020-12-22 | 2020-12-22 | |
| PCT/IB2021/062208 WO2022137178A1 (en) | 2020-12-22 | 2021-12-22 | Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007413A true MX2023007413A (es) | 2023-07-21 |
Family
ID=79287746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007413A MX2023007413A (es) | 2020-12-22 | 2021-12-22 | Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240050457A1 (es) |
| EP (1) | EP4267143A1 (es) |
| JP (1) | JP2024501661A (es) |
| AR (1) | AR124479A1 (es) |
| AU (1) | AU2021405413A1 (es) |
| CA (1) | CA3202926A1 (es) |
| IL (1) | IL303911A (es) |
| MX (1) | MX2023007413A (es) |
| TW (1) | TW202239412A (es) |
| WO (1) | WO2022137178A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| EP2770996B1 (en) | 2011-10-27 | 2016-09-28 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| JP6383403B2 (ja) | 2013-03-15 | 2018-08-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | β−３作動薬および中間体の製造方法 |
| AU2018282104A1 (en) | 2017-06-06 | 2019-12-12 | Urovant Sciences Gmbh | Use of vibegron to treat overactive bladder |
| AU2018282105A1 (en) * | 2017-06-06 | 2019-12-12 | Urovant Sciences Gmbh | Dosing of vibegron for treatment of overactive bladder |
| EP3890743A1 (en) * | 2018-12-05 | 2021-10-13 | Urovant Sciences GmbH | Vibegron for the treatment of overactive bladder symptoms |
-
2021
- 2021-12-22 TW TW110148255A patent/TW202239412A/zh unknown
- 2021-12-22 WO PCT/IB2021/062208 patent/WO2022137178A1/en active Application Filing
- 2021-12-22 EP EP21840154.5A patent/EP4267143A1/en active Pending
- 2021-12-22 JP JP2023538002A patent/JP2024501661A/ja active Pending
- 2021-12-22 CA CA3202926A patent/CA3202926A1/en active Pending
- 2021-12-22 MX MX2023007413A patent/MX2023007413A/es unknown
- 2021-12-22 AU AU2021405413A patent/AU2021405413A1/en active Pending
- 2021-12-22 AR ARP210103632A patent/AR124479A1/es unknown
- 2021-12-22 US US18/258,953 patent/US20240050457A1/en active Pending
- 2021-12-22 IL IL303911A patent/IL303911A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL303911A (en) | 2023-08-01 |
| AU2021405413A1 (en) | 2023-07-06 |
| WO2022137178A1 (en) | 2022-06-30 |
| TW202239412A (zh) | 2022-10-16 |
| US20240050457A1 (en) | 2024-02-15 |
| JP2024501661A (ja) | 2024-01-15 |
| CA3202926A1 (en) | 2022-06-30 |
| AR124479A1 (es) | 2023-03-29 |
| EP4267143A1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4327882A3 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
| IL214373A0 (en) | Use of adipose tissue-derived cells in the preparation of a composition for the treatment of cardiovascular diseases | |
| WO2006127007A3 (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| NO20060912L (no) | Preoperativ behandling for postoperativ smerte | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| US20110306999A1 (en) | Stimulation of specific acupuncture points for vision improvement | |
| MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
| MX2021014634A (es) | Formulaciones farmaceuticas antibacteriales de amplio espectro que comprenden lisozima y metodos de utilizar las mismas. | |
| WO2022008971A3 (en) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho | |
| MX2023007413A (es) | Metodos para monitorear digoxina con el uso de vibegron para tratar veiiga hiperactiva. | |
| EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
| MX2020002206A (es) | Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash). | |
| MX2021007490A (es) | Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides. | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
| WO2020061067A8 (en) | Compositions and methods for treating bone injury | |
| NZ771293A (en) | Dosing regimens for treating hypoxia-associated tissue damage | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| WO2006014162A3 (en) | Methods of using regenerative cells in the treatment of renal diseases and disorders | |
| CR20220247A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| EA202090614A1 (ru) | Способы лечения неалкогольного стеатогепатита (nash) с применением модифицированного фактора роста фибробластов 21 (fgf-21) | |
| WO2024031058A3 (en) | Compositions and methods to treat neurological diseases | |
| Anthonissen et al. | A randomised comparative trial on the effects of shockwave therapy in burn scars |